BioVie initiated with a Buy at Brookline

Brookline analyst Tyler Bussian initiated coverage of BioVie (BIVI) with a Buy rating and $6 price target The company’s lead asset, bezisterim, is currently undergoing testing for the treatment of early Parkinson’s disease and long-COVID, the analyst tells investors in a research note. The firm says the drug offers a new approach targeting neuroinflammation in Parkinson’s patients that has been shown potentially to complement current dopamine replacement therapies and to serve as a single-agent therapy in early disease stages prior to dopaminergic intervention.